ProKidney (PROK) to Release Quarterly Earnings on Monday

Key Points

• ProKidney will release its Q1 2026 results before the market opens on Monday, May 11, with analysts projecting EPS of ($0.13) and revenue of about $0.10 million; the company has a conference call scheduled for May 15 at 4:00 PM ET.
• The stock last traded around $1.90 with a market cap of about $572 million, a 50-day/200-day moving average of $2.04/$2.27, and a 12-month range of $0.54 to $7.13.
• Analyst sentiment is mixed but averages to a "Moderate Buy" with a consensus price target of $7.40, and institutional/hedge fund ownership is substantial at about 51.59%, with several funds recently adding or increasing positions.

ProKidney (NASDAQ:PROK - Get Free Report) is projected to announce its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect the company to announce earnings of ($0.13) per share and revenue of $0.10 million for the quarter. Investors can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Friday, May 15, 2026 at 4:00 PM ET.

ProKidney (NASDAQ:PROK - Get Free Report) last released its earnings results on Wednesday, March 18th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.16) by $0.02. The firm had revenue of $0.23 million during the quarter, compared to analysts' expectations of $0.00 million. On average, analysts expect ProKidney to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

ProKidney Stock Performance

NASDAQ:PROK traded down $0.04 during trading hours on Monday, reaching $1.90. The stock had a trading volume of 323,798 shares, compared to its average volume of 891,202. The stock has a 50 day simple moving average of $2.04 and a 200 day simple moving average of $2.27. ProKidney has a 12-month low of $0.54 and a 12-month high of $7.13. The stock has a market cap of $572.13 million, a P/E ratio of -3.66 and a beta of 1.70.

Analysts Set New Price Targets

A number of analysts have issued reports on PROK shares. Weiss Ratings reissued a "sell (d-)" rating on shares of ProKidney in a research report on Tuesday, April 21st. Wall Street Zen upgraded ProKidney from a "strong sell" rating to a "sell" rating in a research report on Saturday, April 18th. Finally, Jefferies Financial Group upgraded ProKidney to a "strong-buy" rating in a research report on Wednesday, March 18th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, ProKidney currently has an average rating of "Moderate Buy" and a consensus price target of $7.40.

Hedge Funds Weigh In On ProKidney

Hedge funds have recently made changes to their positions in the stock. Cetera Investment Advisers purchased a new position in shares of ProKidney in the fourth quarter valued at $28,000. AQR Capital Management LLC boosted its stake in ProKidney by 106.4% during the first quarter. AQR Capital Management LLC now owns 52,570 shares of the company's stock valued at $46,000 after buying an additional 27,098 shares during the period. EntryPoint Capital LLC bought a new stake in ProKidney during the fourth quarter valued at $65,000. Hudson Bay Capital Management LP bought a new stake in ProKidney during the fourth quarter valued at $101,000. Finally, Jefferies Financial Group Inc. bought a new stake in ProKidney during the third quarter valued at $158,000. 51.59% of the stock is currently owned by hedge funds and other institutional investors.

About ProKidney

ProKidney, Inc NASDAQ: PROK is a clinical-stage biotechnology company focused on developing cell-based therapies for kidney diseases. The company’s research and development activities center on harnessing human-derived proximal tubule cells to address conditions such as acute kidney injury (AKI) and chronic kidney disease (CKD). By targeting the underlying cellular mechanisms of renal injury and dysfunction, ProKidney aims to offer novel regenerative medicine approaches that go beyond current supportive care options.

ProKidney’s lead programs utilize proprietary methods for isolating and expanding renal epithelial cells to create injectable therapeutic products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.